Amgen's MariTide Shows Promising Weight Loss Results in Obesity Drug Trial
Amgen recently unveiled promising results from a critical mid-stage trial of its experimental obesity drug, MariTide, generating significant attention in the competitive weight loss treatment market. The trial revealed that patients taking MariTide experienced up to 20% weight loss on average after a year. Remarkably, the data showed no plateau in weight reduction, suggesting the potential for even greater results with continued use. This distinguishes MariTide as a potential game-changer in a market where achieving and sustaining weight loss is a crucial metric.
For patients with both obesity and Type 2 diabetes—a group known to respond less favorably to weight loss interventions—the drug still delivered up to 17% weight loss. A standout feature of MariTide is its less frequent dosing schedule, with some trial groups receiving the injection monthly or every other month. This may offer a significant advantage over current weekly treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Also Read:- Tourist Boat Tragedy in Red Sea: Four Dead and Three Found Alive After Sinking
- Canada Post Strike Leaves 10 Million Parcels Undelivered Ahead of Black Friday
Despite the positive data, Amgen’s stock took a hit in premarket trading, declining by about 7%. The drop reflected Wall Street's high expectations, as analysts had hoped for weight loss rates of up to 25%. Nonetheless, MariTide’s results remain competitive, especially when compared to Wegovy’s 15% average weight loss over 68 weeks and Zepbound’s 22% reduction over 72 weeks.
MariTide’s novel mechanism could also give it an edge. Unlike existing drugs, it employs a peptide antibody conjugate to activate GLP-1 receptors while blocking GIP receptors. This unique approach may improve how the body processes sugar and fat.
Amgen is already planning its late-stage studies, emphasizing MariTide's potential for quicker weight loss, fewer injections, and possibly better weight maintenance. With the obesity drug market projected to reach $150 billion annually by the early 2030s, MariTide could help Amgen secure a valuable position in this lucrative field.
The second phase of the trial will provide further insights, including long-term weight maintenance and less frequent dosing possibilities. While questions about side effects like bone density remain, Amgen has expressed confidence in the drug’s safety profile. As the company prepares for the next stage of development, MariTide has positioned itself as a formidable contender in the race for effective weight loss solutions.
Read More:
0 Comments